151 related articles for article (PubMed ID: 182328)
1. Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues.
Francis MD; Slough CL; Tofe AJ
Calcif Tissue Res; 1976 Jun; 20(3):303-11. PubMed ID: 182328
[TBL] [Abstract][Full Text] [Related]
2. Distribution of 99mTc-Sn diphosphonate and free 99mTc-pertechnetate in selected soft and hard tissues.
Silberstein EB; Francis MD; Tofe AJ; Slough CL
J Nucl Med; 1975 Jan; 16(1):58-61. PubMed ID: 162948
[TBL] [Abstract][Full Text] [Related]
3. Complexing of reduced technetium and tin(II) by chelating phosphate compounds. II. In vitro stability of pyrophosphate and ethane-1, hydroxy-1, diphosphonate (EHDP) complexes.
Schümichen C; Hohloch M; Hoffmann G
Nuklearmedizin; 1979 May; 18(2):105-9. PubMed ID: 38437
[TBL] [Abstract][Full Text] [Related]
4. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
[TBL] [Abstract][Full Text] [Related]
5. Biokinetics of bone tracers by means of deconvolution analysis--comparison of 99mTc MDP, 99mTc DPD and 99mTc EHDP.
Knop J; Stritzke P; Kröger E; Schneider C; Wasmus G
Nuklearmedizin; 1982 Aug; 21(4):145-9. PubMed ID: 6216459
[TBL] [Abstract][Full Text] [Related]
6. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc.
Hambright P; McRae J; Valk PE; Bearden AJ; Shipley BA
J Nucl Med; 1975 Jun; 16(6):478-82. PubMed ID: 808594
[TBL] [Abstract][Full Text] [Related]
7. Uptake of Tc-99m monophosphate complexes in bone and myocardial necrosis in animals.
Kung HF; Ackerhalt R; Blau M
J Nucl Med; 1978 Sep; 19(9):1027-31. PubMed ID: 690703
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of three diphosphonates: in vitro adsorption (C- 14 labeled) and in vivo osteogenic uptake (Tc-99m complexed).
Francis MD; Ferguson DL; Tofe AJ; Bevan JA; Michaels SE
J Nucl Med; 1980 Dec; 21(12):1185-9. PubMed ID: 6449567
[TBL] [Abstract][Full Text] [Related]
9. The influence of the method of preparation of the bone scanning agent 99mTc(Sn)EHDP on its tissue distribution in the rat.
Van den Brand JA; Das HA; Dekker BG; de Ligny CL; Van den Hamer CJ
Int J Appl Radiat Isot; 1982 Oct; 33(10):917-28. PubMed ID: 6818161
[TBL] [Abstract][Full Text] [Related]
10. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-labelled Cu(I)-EHDP, a potential skeletal imaging agent.
Agha NH; Al-Hilli AM; Hassen HA
Nuklearmedizin; 1981 Dec; 20(6):299-304. PubMed ID: 6799937
[TBL] [Abstract][Full Text] [Related]
12. [Study on tumor affinity of technetium-99m-labeled radiopharmaceuticals. (2) 99mTc-Sn-diphosphonate (99mTc-EHDP), 99mTc-Sn-dimercaptosuccinic acid (99mTc-DMSA), and 99mTc-Sn-diethyl stilbestrol diphosphate (99mTc-DSDP)].
Ito K; Kobayashi S; Hisada K; Tonami N; Ando A
Radioisotopes; 1976 Oct; 25(10):622-9. PubMed ID: 1037404
[TBL] [Abstract][Full Text] [Related]
13. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals.
Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
J Nucl Med; 1980 Oct; 21(10):961-6. PubMed ID: 6252298
[TBL] [Abstract][Full Text] [Related]
14. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication.
Fogelman I; Pearson DW; Bessent RG; Tofe AJ; Francis MD
J Nucl Med; 1981 Oct; 22(10):880-3. PubMed ID: 6457135
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of osteotropic radiopharmaceuticals. II. Plasma clearance of 18F and 99mTc-EHDP (author's transl)].
Creutzig H
Rofo; 1975 Oct; 123(4):313-8. PubMed ID: 129388
[TBL] [Abstract][Full Text] [Related]
16. Whole-body autoradiography of 99Tcm-labelled ethylene-1-hydroxy-1, 1-diphosphonate (EHDP) in young rats.
Rohlin M
Acta Radiol Ther Phys Biol; 1976 Oct; 15(5):410-6. PubMed ID: 827191
[TBL] [Abstract][Full Text] [Related]
17. Technetium-99m-labeled phosphonic acid analog of serine: bone uptake.
Surh Y; Spencer RP; Spitznagle LA; Hosain F; Lejczak B
J Nucl Med; 1986 Jun; 27(6):847-9. PubMed ID: 3712097
[TBL] [Abstract][Full Text] [Related]
18. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model.
Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
J Nucl Med; 1980 Oct; 21(10):967-70. PubMed ID: 6252299
[TBL] [Abstract][Full Text] [Related]
19. Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues.
Buja LM; Tofe AJ; Kulkarni PV; Mukherjee A; Parkey RW; Francis MD; Bonte FJ; Willerson JT
J Clin Invest; 1977 Sep; 60(3):724-40. PubMed ID: 893676
[TBL] [Abstract][Full Text] [Related]
20. The effect of DMSO treatment on the composition of 99mTc(Sn)EHDP.
de Groot GJ; Das HA; de Ligny CL
Int J Rad Appl Instrum A; 1986; 37(6):487-90. PubMed ID: 3019948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
